Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
NCT01050855Phase 2Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jan 2008
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in immunodeficiency, hemoglobinopathy, sponsored by Children's Hospital of Philadelphia. Started Jan 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
immunodeficiencyhemoglobinopathy
Beyond the preview
Go deeper on NCT01050855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01050855.